News
-
-
-
COMMUNIQUÉ DE PRESSE
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte to present updates on near-term catalysts at Emerging Growth Conference; Initial results show crofelemer may extend infants' lives with MVID; Jaguar completes FDA meeting on crofelemer trial for MVID treatment -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap -
